Pharma’s expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation

Photo caption: Drug patents don’t necessarily spur companies to innovate so much as restrict access to their IP. Photo credit: Andrii Zastrozhnov / iStock via Getty Images Plus. Article by Lucy Xiaolu Wang. The Conversation – December 5, 2022.

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially to low- and middle-income countries, or LMICs. […]

Click here to view original web page at theconversation.com